New Rhein
New Rhein is a private equity investment firm based in Philadelphia, specializing in healthcare therapeutics and medical devices. The firm is comprised of partners and associates with extensive operational and transactional experience in the industry. New Rhein focuses on investing in businesses that apply proven products in new ways, such as new indications and dosage forms. The company assembles syndicates of investors who possess a wealth of experience and a broad network of relationships, which they leverage to support portfolio companies in various areas, including development, regulatory affairs, reimbursement, marketing, and contract manufacturing. Additionally, New Rhein assists its portfolio companies in understanding the preferences of strategic partners, helping them to build a compelling value proposition. Previous investments have included sectors such as ophthalmic pharmaceuticals, molecular diagnostics, and respiratory drug/device inhalers.
Butterfly Medical Ltd is a medical device company based in Yokne'am, Israel, founded in 2014. The company specializes in developing an innovative implantable device designed to treat Benign Prostatic Hyperplasia (BPH), commonly known as enlarged prostate. This device offers a fast, simple, and minimally invasive alternative to traditional BPH treatments, including medication and surgery. It can be placed in under 10 minutes in an office setting, using local anesthesia and without the need for surgical incisions, heating, or tissue removal. Butterfly Medical's patented device aims to provide a long-term solution with minimal side effects, eliminating the need for hospitalization or general anesthesia. Early clinical trial results have shown promise, with successful openings of blocked urethras and no reported side effects in patients. The company is set to conduct further clinical studies at leading medical centers in Europe.
American Injectables is a sterile injectable manufacturer of parenteral drugs with a world-class facility focused on ready-to-use pre-filled syringes and vials.
Neuraptive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics and medical products for the treatment of peripheral nerve injuries (PNI). The company offers a range of products, including AxoFuse, a nerve repair system designed to prevent nerve degeneration and limb atrophy; AxoTrim, a surgical instrument for preparing nerves for suturing; and AxoBond, which secures surgically repaired nerves during recovery. Additionally, Neuraptive is working on NTX-001, a drug-device product intended for use in surgical nerve repairs and reconstructive procedures. Founded in 2016, the company aims to address the unmet medical needs of patients and physicians dealing with acute nerve injuries. Neuraptive is headquartered in Lafayette, Colorado, with additional offices in Philadelphia, Pennsylvania, and Louisville, Colorado.
Neuraptive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics and medical products for the treatment of peripheral nerve injuries (PNI). The company offers a range of products, including AxoFuse, a nerve repair system designed to prevent nerve degeneration and limb atrophy; AxoTrim, a surgical instrument for preparing nerves for suturing; and AxoBond, which secures surgically repaired nerves during recovery. Additionally, Neuraptive is working on NTX-001, a drug-device product intended for use in surgical nerve repairs and reconstructive procedures. Founded in 2016, the company aims to address the unmet medical needs of patients and physicians dealing with acute nerve injuries. Neuraptive is headquartered in Lafayette, Colorado, with additional offices in Philadelphia, Pennsylvania, and Louisville, Colorado.
Softhale NV develops inhalation products for respiratory treatment. It offers Soft Mist Inhalation(SMI) device for lungs. The company was founded in 2016 and is based in Diepenbeek, Belgium.
Chase Pharmaceuticals Corporation, Inc., a specialty pharmaceutical company, focuses on the development of medications for the treatment of Alzheimer’s disease. Its product, CPC-252, is a transdermal formulation for the treatment of Alzheimer's disease and Parkinsonism dementia. The company was incorporated in 2007 and is based in Washington, District of Columbia. As of November 22, 2016, Chase Pharmaceuticals Corporation, Inc. operates as a subsidiary of Allergan plc.
Biocartis Group NV is a molecular diagnostics company that specializes in developing diagnostic solutions with a strong emphasis on oncology. The company’s proprietary Idylla platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that aids in treatment selection and monitoring. Biocartis offers a range of diagnostic tests, including solid biopsy tests for mutations such as BRAF, KRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. In addition to its diagnostic offerings, the company collaborates with major pharmaceutical firms like AstraZeneca and Bristol-Myers Squibb to create companion diagnostics that enhance treatment efficacy in cancer care. Founded in 2007, Biocartis is headquartered in Mechelen, Belgium, and strives to improve personalized medical treatments through its innovative diagnostic systems.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.